GMP-approved biopharmaceutical manufacturer and CDMO with multi-facility operations across Europe and South America
mAbxience manufactures biopharmaceuticals and operates a CDMO business across three GMP-approved facilities, with active market approvals and a pipeline in development. The tech stack is heavily weighted toward manufacturing-automation infrastructure (Siemens SCADA, DeltaV, PROFINET, EtherNet/IP)—a typical pattern for regulated pharma—while SAP and LIMS handle enterprise data and lab operations. The hiring surge is concentrated in manufacturing roles across Spain and Argentina, paired with active initiatives on equipment qualification, process validation, and automation, suggesting facility expansion and capacity buildout.
mAbxience is a Spanish biopharmaceutical company founded in 2009, headquartered in Madrid, with over 1,000 employees. The company develops, manufactures, and commercializes biosimilars and monoclonal antibodies in therapeutic areas including hematology, autoimmune disease, and oncology. Three manufacturing facilities in Europe and South America hold regulatory approvals from the FDA and EMA. The business operates dual channels: a direct B2B presence in over 100 markets and a CDMO service line supporting contract manufacturing for third-party partners across a network of more than 30 collaborators. Key operational challenges center on compliance assurance, capacity planning, aseptic fill-finish optimization, and supply-chain efficiency.
Siemens automation (TIA Portal, PCS 7, WinCC), DeltaV distributed control, LIMS for lab data, HPLC/UPLC/UHPLC for analytical testing, SAP for ERP, and PROFINET/EtherNet/IP/BACnet for network infrastructure across GMP facilities.
Three GMP-approved multi-product facilities located in Europe and South America, holding regulatory approvals from the FDA, EMA, and other bodies, with current hiring concentrated in Spain and Argentina.
Other companies in the same industry, closest in size